{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:53:18Z","timestamp":1791118398913,"version":"4.1.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.blre.2009.01.001","type":"journal-article","created":{"date-parts":[[2009,2,26]],"date-time":"2009-02-26T10:09:48Z","timestamp":1235642988000},"page":"157-165","source":"Crossref","is-referenced-by-count":68,"title":["Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders"],"prefix":"10.1016","volume":"23","author":[{"given":"Peter","family":"Valent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2009.01.001_bib1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev.me.44.020193.000505","article-title":"The biology of the eosinophilic leukocyte","volume":"44","author":"Gleich","year":"1993","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.blre.2009.01.001_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0952-7915(94)90038-8","article-title":"Eosinophils: structure and functions","volume":"6","author":"Weller","year":"1994","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.blre.2009.01.001_bib3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1067\/mai.2000.105712","article-title":"Mechanisms of eosinophil-associated inflammation","volume":"105","author":"Gleich","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.blre.2009.01.001_bib4","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2222.2008.02958.x","article-title":"Eosinophils: biological properties and role in health and disease","volume":"38","author":"Hogan","year":"2008","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.blre.2009.01.001_bib5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.iac.2007.07.004","article-title":"Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders","volume":"27","author":"Ackerman","year":"2007","journal-title":"Immunol Allergy Clin N Am"},{"key":"10.1016\/j.blre.2009.01.001_bib6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.iac.2007.07.001","article-title":"Cardiovascular manifestations of hypereosinophilic syndromes","volume":"27","author":"Ogbogu","year":"2007","journal-title":"Immunol Allergy Clin N Am"},{"key":"10.1016\/j.blre.2009.01.001_bib7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood.V64.1.78.78","article-title":"Identification of pure and mixed basophil colonies in culture of human peripheral blood and marrow cells","volume":"64","author":"Leary","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.blre.2009.01.001_bib8","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1182\/blood.V66.2.312.312","article-title":"Heterogeneity of human peripheral blood eosinophil-type colonies: evidence for a common basophil\u2013eosinophil progenitor","volume":"66","author":"Denburg","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.blre.2009.01.001_bib9","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood.V83.6.1515.1515","article-title":"Lymphoid and myeloid differentiation of single human CD34+, HLA-DR+, CD38\u2212 hematopoietic stem cells","volume":"83","author":"Huang","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.blre.2009.01.001_bib10","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S0091-6749(96)70159-8","article-title":"Early commitment to the eosinophil lineage by cultured human peripheral blood CD34+ cells: messenger RNA analysis","volume":"98","author":"Shalit","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.blre.2009.01.001_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1398-9995.1998.tb04935.x","article-title":"Hemopoietic progenitors and cytokines in allergic inflammation","volume":"53","author":"Denburg","year":"1998","journal-title":"Allergy"},{"key":"10.1016\/j.blre.2009.01.001_bib12","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1034\/j.1398-9995.1999.00756.x","article-title":"Circulating eosinophil\/basophil progenitors and nasal mucosal cytokines in seasonal allergic rhinitis","volume":"54","author":"Linden","year":"1999","journal-title":"Allergy"},{"key":"10.1016\/j.blre.2009.01.001_bib13","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/eji.1830171210","article-title":"Recombinant human interleukin 5 is an eosinophil differentiation factor but has no activity in standard human B cell growth factor assays","volume":"17","author":"Clutterbuck","year":"1987","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.blre.2009.01.001_bib14","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1073\/pnas.85.7.2288","article-title":"Selective differentiation and proliferation of hematopoietic cells induced by recombinant human interleukins","volume":"85","author":"Saito","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.blre.2009.01.001_bib15","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1182\/blood.V73.7.1763.1763","article-title":"Interleukin-3 is a differentiation factor for human basophils","volume":"73","author":"Valent","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.blre.2009.01.001_bib16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/oxfordjournals.bmb.a072328","article-title":"T cells and lymphokines","volume":"45","author":"Feldmann","year":"1989","journal-title":"Br Med Bull"},{"key":"10.1016\/j.blre.2009.01.001_bib17","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1398-9995.1992.tb00662.x","article-title":"Human Th1 and Th2 lymphocytes: their role in the pathophysiology of atopy","volume":"47","author":"Del Prete","year":"1992","journal-title":"Allergy"},{"key":"10.1016\/j.blre.2009.01.001_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1398-9995.1995.tb04272.x","article-title":"Microenvironmental influences on inflammatory cell differentiation","volume":"50","author":"Denburg","year":"1995","journal-title":"Allergy"},{"key":"10.1016\/j.blre.2009.01.001_bib19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1089\/107999004323065057","article-title":"The role of human mast cell-derived cytokines in eosinophil biology","volume":"24","author":"Shakoory","year":"2004","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.blre.2009.01.001_bib20","doi-asserted-by":"crossref","first-page":"24741","DOI":"10.1016\/S0021-9258(18)54292-7","article-title":"Interleukin-5, interleukin-3, and granulocyte\u2013macrophage colony-stimulating factor cross-compete for binding to cell surface receptors on human eosinophils","volume":"266","author":"Lopez","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2009.01.001_bib21","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0167-5699(92)90025-3","article-title":"GM-CSF, IL-3 and IL-5: cross-competition on human haemopoietic cells","volume":"13","author":"Lopez","year":"1992","journal-title":"Immunol Today"},{"key":"10.1016\/j.blre.2009.01.001_bib22","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/infdis\/129.5.606","article-title":"The eosinophil in infection diseases","volume":"129","author":"Kay","year":"1974","journal-title":"J Infect Dis"},{"key":"10.1016\/j.blre.2009.01.001_bib23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000069956","article-title":"Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update","volume":"206","author":"Tas","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.blre.2009.01.001_bib24","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejim.2006.09.031","article-title":"Eosinophilia: a study of 100 hospitalized patients","volume":"18","author":"Sade","year":"2007","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.blre.2009.01.001_bib25","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2141.2006.06038.x","article-title":"Eosinophilia: secondary, clonal and idiopathic","volume":"133","author":"Tefferi","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2009.01.001_bib26","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/infdis\/145.2.613","article-title":"The ecology of eosinophils in schistosomiasis","volume":"145","author":"Mahmoud","year":"1982","journal-title":"J Infect Dis"},{"key":"10.1016\/j.blre.2009.01.001_bib27","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00296-004-0469-6","article-title":"Eosinophilia in rheumatologic diseases: a prospective study of 1000 cases","volume":"24","author":"Kargili","year":"2004","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.blre.2009.01.001_bib28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/01.cji.0000211324.53396.f6","article-title":"Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors","volume":"30","author":"Lotfi","year":"2007","journal-title":"J Immunother"},{"key":"10.1016\/j.blre.2009.01.001_bib29","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.iac.2007.07.008","article-title":"Evaluation and differential diagnosis of marked, persistent eosinophilia","volume":"27","author":"Nutman","year":"2007","journal-title":"Immunol Allergy Clin N Am"},{"key":"10.1016\/j.blre.2009.01.001_bib30","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.jaci.2007.02.010","article-title":"Eosinophilic disorders","volume":"119","author":"Simon","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.blre.2009.01.001_bib31","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.jaci.2006.02.042","article-title":"The hypereosinophilic syndromes working group. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report","volume":"117","author":"Klion","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.blre.2009.01.001_bib32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1750-1172-2-37","article-title":"Hypereosinophilic syndromes","volume":"2","author":"Roufosse","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.blre.2009.01.001_bib33","first-page":"2","article-title":"Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome","volume":"95","author":"Bain","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2009.01.001_bib34","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.beha.2005.07.013","article-title":"Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy","volume":"19","author":"Gotlib","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.blre.2009.01.001_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-007-0403-6","article-title":"The diagnosis of BCR\/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers","volume":"87","author":"Haferlach","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2009.01.001_bib36","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2009.01.001_bib37","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.blre.2009.01.001_bib38","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.iac.2007.06.001","article-title":"Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome","volume":"27","author":"Bain","year":"2007","journal-title":"Immunol Allergy Clin N Am"},{"key":"10.1016\/j.blre.2009.01.001_bib39","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/bmb\/ldm008","article-title":"Eosinophilic leukaemia","volume":"81\u201382","author":"Fletcher","year":"2007","journal-title":"Br Med Bull"},{"key":"10.1016\/j.blre.2009.01.001_bib40","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2009.01.001_bib41","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2009.01.001_bib42","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2009.01.001_bib43","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2009.01.001_bib44","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2002-10-3103","article-title":"Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders","volume":"101","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2009.01.001_bib45","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000085562","article-title":"Modern diagnosis and treatment of primary eosinophilia","volume":"114","author":"Tefferi","year":"2005","journal-title":"Acta Haematol"},{"key":"10.1016\/j.blre.2009.01.001_bib46","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/00029330-200805020-00001","article-title":"FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib","volume":"121","author":"Wang","year":"2008","journal-title":"Chin Med J"},{"key":"10.1016\/j.blre.2009.01.001_bib47","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1038\/sj.leu.2404977","article-title":"The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus","volume":"21","author":"Burgstaller","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2009.01.001_bib48","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1182\/blood-2005-08-3153","article-title":"The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)\/chronic eosinophilic leukemia (CEL)-like disease","volume":"107","author":"Yamada","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2009.01.001_bib49","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-2362.2008.01950.x","article-title":"Mixed-lineage eosinophil\/basophil crisis in MDS: a rare form of progression","volume":"38","author":"Wimazal","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.blre.2009.01.001_bib50","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1182\/blood-2002-03-0947","article-title":"Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia","volume":"101","author":"Matsushima","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2009.01.001_bib51","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0145-2126(01)00172-2","article-title":"A case of smouldering mastocytosis with peripheral blood eosinophilia and lymphadenopathy","volume":"26","author":"Hauswirth","year":"2002","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2009.01.001_bib52","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaci.2007.03.015","article-title":"Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance","volume":"120","author":"B\u00f6hm","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.blre.2009.01.001_bib53","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1111\/1523-1747.ep12468882","article-title":"Classification and diagnosis of mastocytosis: current status","volume":"96","author":"Metcalfe","year":"1991","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.blre.2009.01.001_bib54","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S0145-2126(03)00093-6","article-title":"Multilineage hematopoietic involvement in systemic mastocytosis","volume":"27","author":"Akin","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2009.01.001_bib55","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0145-2126(03)00065-1","article-title":"Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia","volume":"27","author":"Pardanani","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2009.01.001_bib56","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ajh.20088","article-title":"Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis","volume":"77","author":"Bain","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2009.01.001_bib57","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2362.2007.01757.x","article-title":"FIP1L1\/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.blre.2009.01.001_bib58","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJM199910073411503","article-title":"Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia","volume":"341","author":"Simon","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2009.01.001_bib59","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1046\/j.1365-2141.2000.02097.x","article-title":"Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome","volume":"109","author":"Roufosse","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2009.01.001_bib60","first-page":"51","article-title":"Chronic eosinophilic leukaemia, not otherwise specified","volume":"vol. 2","author":"Bain","year":"2008"},{"key":"10.1016\/j.blre.2009.01.001_bib61","first-page":"68","article-title":"Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1","volume":"vol. 2","author":"Bain","year":"2008"},{"key":"10.1016\/j.blre.2009.01.001_bib62","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0025-6196(11)62962-5","article-title":"Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment","volume":"80","author":"Tefferi","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.blre.2009.01.001_bib63","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2005-05-1932","article-title":"The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo","volume":"106","author":"Stover","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2009.01.001_bib64","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.exphem.2008.04.017","article-title":"Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFR\u03b1","volume":"36","author":"Baumgartner","year":"2008","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2009.01.001_bib65","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2009.01.001_bib66","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1535-6108(03)00108-9","article-title":"PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease","volume":"3","author":"Cools","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2009.01.001_bib67","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2006-02-004457","article-title":"Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant","volume":"108","author":"Lierman","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2009.01.001_bib68","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1182\/blood-2006-01-0285","article-title":"The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib)","volume":"107","author":"von Bubnoff","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2009.01.001_bib69","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3324\/haematol.10328","article-title":"Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders","volume":"92","author":"Reiter","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2009.01.001_bib70","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/1078-0432.CCR-08-1302","article-title":"Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia","volume":"15","author":"Verstovsek","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2009.01.001_bib71","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/cncr.22920","article-title":"A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia","volume":"110","author":"Kalac","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2009.01.001_bib72","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2006-10-050054","article-title":"Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia","volume":"109","author":"Jovanovic","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2009.01.001_bib73","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/leu.2008.287","article-title":"Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias","volume":"22","author":"Gotlib","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2009.01.001_bib74","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Mepolizumab HES study group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N Engl J Med"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X09000095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X09000095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T11:03:01Z","timestamp":1633172581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X09000095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0268960X09000095"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2009.01.001","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}